Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

XTLB

XTL Biopharmaceuticals (XTLB)

XTL Biopharmaceuticals Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:XTLB
DateHeureSourceTitreSymboleSociété
19/11/202423h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
14/08/202415h15GlobeNewswire Inc.XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 MillionNASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/06/202415h15GlobeNewswire Inc.XTL Entered Definitive Agreement to Acquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/03/202415h15GlobeNewswire Inc.XTL To Aquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322h00GlobeNewswire Inc.XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322h00GlobeNewswire Inc.XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
16/05/202317h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
01/02/202315h53Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
30/03/202223h16Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
08/06/202112h05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/05/202117h31Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/08/202015h24Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
13/01/202012h39Edgar (US Regulatory)Amended Report of Foreign Issuer (6-k/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
01/11/201815h09PR Newswire (US)XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/07/201815h09PR Newswire (US)XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
29/05/201823h37PR Newswire (US)XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
07/03/201822h05Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
28/02/201822h04Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/01/201821h51Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
06/12/201718h08PR Newswire (US)XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing RequirementsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
27/11/201716h30PR Newswire (US)XTL Biopharmaceuticals Reports Third Quarter 2017 Financial ResultsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
23/10/201717h23PR Newswire (US)XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing RequirementsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
26/09/201715h23PR Newswire (US)XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
12/09/201716h24PR Newswire (US)XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's SyndromeNASDAQ:XTLBXTL Biopharmaceuticals Ltd
15/06/201715h38PR Newswire (US)XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
27/04/201715h50PR Newswire (US)XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of DirectorsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/04/201715h10PR Newswire (US)XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s SyndromeNASDAQ:XTLBXTL Biopharmaceuticals Ltd
30/03/201714h55PR Newswire (US)XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
29/03/201723h01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
22/03/201714h22PR Newswire (US)XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing InvestorsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:XTLB